The effectiveness of boosters developed specifically to match potential newer variants could be greater and would last longer than boosters using current vaccines.
Even for the Delta variant, vaccine efficacy against severe Covid-19 is so high that booster doses for the general population are not appropriate at this stage in the pandemic, an expert review by an international group of scientists, including some from the World Health Organisation (WHO) and US Food and Drug Administration (FDA), has concluded.
The review, published in The Lancet on Monday, summarises currently available evidence from randomised controlled trials and observational studies published in peer-reviewed journals and preprint servers.
“Taken as a whole, currently available studies do not provide credible evidence of substantially declining protection against severe disease, which is the primary goal of vaccination. The limited supply of these vaccines will save most lives if made available to people who are at appreciable risk of serious disease. Even if some gain can ultimately be obtained from boosting, it will not outweigh the benefits of providing initial protection to the unvaccinated. If vaccines are deployed where they would do the most good, they could hasten the end of the pandemic by inhibiting further evolution of variants,” said lead author Dr Ana-Maria Henao-Restrepo, WHO.
A consistent finding from the observational studies is that vaccines remain highly effective against severe disease, including that from all the main viral variants. Averaging the results reported from the observational studies, vaccination had 95 per cent efficacy against severe disease –both from the Delta and the Alpha variant, and over 80 per cent efficacy at protecting against any infection from these variants.
The authors of the review noted that even if levels of antibodies in vaccinated individuals wane over time, this does not necessarily predict reductions in the efficacy of vaccines against severe disease. This could be because protection against severe disease is mediated not only by antibody responses, which might be relatively short-lived for some vaccines, but also by memory responses and cell-mediated immunity, which are generally longer-lived.
The ability of vaccines to elicit an antibody response against current variants indicates that these variants have not yet evolved to the point at which they are likely to escape the memory immune response induced by the vaccines, the review noted.
If boosters are ultimately to be used, there will be a need to identify specific circumstances where the benefits outweigh the risks, the authors said.
Even if new variants that can escape the current vaccines are going to evolve, they are most likely to do so from strains that have already become widely prevalent. Therefore, the effectiveness of boosters developed specifically to match potential newer variants could be greater and would last longer than boosters using current vaccines. A similar strategy is used for influenza shots, for which each annual vaccine is based on the most current data about circulating strains, which increases the likelihood that the vaccine will remain effective even if there is a further evolution in strain.
“The vaccines that are currently available are safe, effective, and save lives. Although the idea of further reducing the number of Covid-19 cases by enhancing immunity in vaccinated people is appealing, any decision to do so should be evidence-based and consider the benefits and risks for individuals and society. These high-stakes decisions should be based on robust evidence and international scientific discussion,” said co-author Dr Soumya Swaminathan, Chief Scientist, WHO.
Source: Read Full Article